Table 1 Cohort characteristics by metastatic site.

From: Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinoma

 

Lymph node

Lung

Bone

IO–IO

(n=21)

IO–TKI

(n=15)

P-value

IO–IO

(n=62)

IO–TKI

(n=70)

P-value

IO–IO

(n=34)

IO–TKI

(n=46)

P-value

Age, median, (range)

70 (27-87)

70 (26-85)

 

70 (32-86)

70 (44-89)

 

70 (25-86)

70 (45-85)

 

Sex

18/3

11/4

0.24

48/14

49/21

0.43

29/5

37/9

0.77

eGFR, median, (range)

50 (5-84)

50 (16-79)

 

50 (4-102)

50 (5-91)

 

50 (4-102)

50 (5-98)

 

Metastatic site, n (%)

         

Lung

0

0

 

62 (100)

70 (100)

 

14 (41.2)

17 (37.0)

0.82

Bone

0

0

 

0

0

 

34 (100)

46 (100)

 

Liver

0

0

 

0

0

 

0

0

 

Brain

0

0

 

0

0

 

0

0

 

Lymph node

21 (100)

15 (100)

 

14 (22.6)

21 (30)

0.43

7 (20.6)

10 (21.7)

1.0

Histology, n (%)

         

Clear cell

9 (42.9)

6 (40)

0.71

44 (71.0)

56 (80)

0.3

24 (70.6)

33 (71.7)

0.74

Papillary

4 (19.0)

4 (26.7)

 

3 (4.8)

3 (4.3)

 

0 (0)

3 (6.5)

 

Unclassified

4 (19.0)

0 (0)

 

3 (4.8)

1 (1.4)

 

1 (2.9)

0 (0)

 

HD-related

1 (4.8)

0 (0)

 

0

2 (2.9)

 

1 (2.9)

0 (0)

 

Chromophobe

0 (0)

0 (0)

 

0

0

 

0 (0)

0 (0)

 

Others

3 (14.3)

1 (6.7)

 

4 (6.5)

1 (1.4)

 

3 (8.8)

2 (4.3)

 

None

0 (0)

4 (26.7)

 

8 (12.9)

7 (0.1)

 

3 (8.8)

3 (6.5)

 

Presence of sarcomatoid component

2 (9.5)

0 (0)

1.0

5 (8.1)

10 (14.3)

0.27

1 (2.9)

3 (6.5)

0.61

Treatment

         

Nivolumab +

Ipilimumab

21 (100)

  

62 (100)

  

34 (100)

  

Pembrolizumab +

Axitinib

 

5 (33.3)

  

32 (45.7)

  

9 (19.6)

 

Avelumab +

Axitinib

 

4 (26.7)

  

12 (17.1)

  

4 (8.7)

 

Nivolumab +

Cabozantinib

 

3 (20)

  

13 (18.6)

  

19 (41.3)

 

Pembrolizumab +

Lenvatinib

 

3 (20)

  

13 (18.6)

  

14 (30.4)

 

Confirmation of histology, n (%)

         

Nephrectomy

11 (52.3)

7 (46.7)

1.0

29 (46.8)

41 (58.6)

0.16

13 (38.2)

15 (32.6)

0.81

Partial nephrectomy

1 (4.8)

0 (0)

 

1 (1.6)

5 (7.1)

 

4 (11.8)

4 (8.7)

 

Biopsy

9 (42.9)

4 (26.7)

 

24 (38.7)

16 (22.9)

 

12 (35.3)

19 (41.3)

 

IMDC at 1st line, n (%)

         

Intermediate/poor

14/7

11/4

0.72

38/24

55/15

0.036

23/11

28/18

0.64

 

Liver

Liver and/or bone

Brain

IO–IO

(n=11)

IO–TKI

(n=11)

P-value

IO–IO

(n=63)

IO–TKI

(n=82)

P-value

IO–IO

(n=10)

IO–TKI

(n=6)

P-value

Age, median, (range)

70 (54-74)

70 (58-80)

 

70 (25-86)

70 (40-88)

 

70 (53-79)

70 (53-83)

 

Sex

8/3

9/2

1.0

52/11

63/19

0.42

5/5

3/3

1.0

eGFR, median, (range)

50 (8-77)

50 (32-102)

 

50 (4-160)

50 (5-102)

 

50 (42-116)

50 (35-110)

 

Metastatic site, n (%)

         

Lung

9 (81.8)

6 (54.5)

0.36

33 (52.4)

40 (48.8)

0.74

9 (90)

5 (83.3)

1.0

Bone

0 (0)

0 (0)

 

47 (74.6)

64 (78.0)

0.69

2 (20)

1 (16.7)

1.0

Liver

11 (100)

11 (100)

 

24 (38.1)

28 (34.1)

0.73

0 (0)

1 (16.7)

0.38

Brain

0 (0)

0 (0)

 

0 (0)

0 (0)

 

10 (100)

6 (100)

 

Lymph node

8 (72.7)

5 (45.5)

0.39

20 (31.7)

27 (32.9)

0.43

4 (40)

3 (50)

1.0

Treatment

         

Nivolumab +

Ipilimumab

11 (100)

  

63 (100)

  

10 (100)

  

Pembrolizumab +

Axitinib

 

3 (27.2)

  

19 (23.2)

  

1 (16.7)

 

Avelumab +

Axitinib

 

0 (0)

  

4 (4.9)

  

2 (33.3)

 

Nivolumab +

Cabozantinib

 

3 (27.2)

  

29 (35.4)

  

1 (26.7)

 

Pembrolizumab +

Lenvatinib

 

5 (45.5)

  

30 (36.6)

  

2 (33.3)

 

Histology, n (%)

         

Clear cell

9 (81.8)

7 (63.6)

0.47

45 (71.4)

55 (67.0)

0.3

6 (60)

5 (83.7)

0.49

Papillary

0 (0)

2 (18.2)

 

1 (1.6)

7 (8.5)

 

0 (0)

0 (0)

 

Unclassified

0 (0)

0 (0)

 

3 (4.8)

2 (0)

 

1 (10)

0 (0)

 

HD-related

0 (0)

0 (0)

 

0 (0)

0 (0)

 

0 (0)

0 (0)

 

Chromophobe

0 (0)

0 (0)

 

0 (0)

1 (1.2)

 

0 (0)

0 (0)

 

Others

0 (0)

0 (0)

 

4 (6.3)

2 (2.4)

 

1 (10)

0 (0)

 

None

2 (18.2)

2 (18.2)

 

8 (12.7)

15 (18.3)

 

2 (20)

1 (16.7)

 

Presence of sarcomatoid component

1 (9.1)

0 (0)

1.0

2 (3.2)

4 (4.9)

0.27

2 (20)

0 (0)

0.49

Confirmation of histology, n (%)

         

Nephrectomy

5 (45.5)

4 (36.4)

1.0

23 (36.5)

28 (4.9)

0.16

4 (40)

1 (16.7)

0.59

Partial nephrectomy

0 (0)

0 (0)

 

5 (7.9)

5 (6.0)

 

0 (0)

0 (0)

 

Biopsy

5 (45.5)

5 (45.5)

 

24 (38.1)

33 (40.2)

 

5 (50)

3 (50)

 

IMDC at 1st line, n (%)

         

Intermediate/poor

6/5

6/5

1.0

37/26

47/35

 

5/5

4/2

0.63

  1. eGFR, estimated glomerular filtration rate; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IO, immuno-oncology; TKI, tyrosine kinase inhibitor.
Back to article page